Anticoagulation Management after Mitral Valve Replacement with the St. Jude Medical Prosthesis.
- Author:
Chong Whan KIM
1
;
Young Tae KIM
Author Information
1. Department of Thoracic and Cardiovascular Surgery, College of Medicine, Seoul National University, Korea.
- Publication Type:Original Article
- Keywords:
Anticoagulation;
Heart valve replacement;
Heart valve prosthesis
- MeSH:
Ambulatory Care Facilities;
Aortic Valve;
Atrial Fibrillation;
Compliance;
Follow-Up Studies;
Heart Valve Prosthesis;
Heart Valves;
Hemorrhage;
Humans;
Incidence;
International Normalized Ratio;
Mitral Valve*;
Prostheses and Implants*;
Prothrombin Time;
Risk Factors;
Thromboembolism;
Warfarin
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
1998;31(12):1172-1182
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Primary goal of anticoagulation treatment in patients with mechanical heart valve is the effective prevention of thromboembolism and safe avoidance of bleeding as well. MATERIAL AND METHOD: Two-hundred and nine patients with the St. Jude Medical prosthesis operated on between 1984 and 1995, for mitral (MVR 122), aortic (AVR 39) and double mitral and aortic valve replacement (DVR 48) respectively, were studied on the practically achieved levels of anticoagulation and the clinical outcomes. Patients were on Coumadin and followed up by monthly visit to outpatient clinic for examination and prothrombin time measurement to adjust the International Normalized Ratios (INRs) within the low-intensity target range between 1.5 and 2.5. RESULT: A total anticoagulation follow-up period was 1082.0 patient- years (mean 62.1 months) and INRs of 10,205 measurements were available for evaluation. The accomplished INRs among the replacement groups were not significantly different and only 65% of INRs were within the target range. And, in individual patients, only 37% of patients had INRs included within the target range in more than 70% of tests during follow-up period. The levels of INRs in patients with atrial fibrillation, which was found in 57% of patients, were definitely higher than the ones measured in patients with regular rhythm (p<0.001). Thromboembolisms were experienced by 15 patients with the incidence of 1.265%/patient- year (MVR 1.412%, AVR 0.462% and DVR 1.531%/patient-year) and major bleeding by 4 patients with the incidence of 0.337%/patient-year (MVR 0.424%, AVR none and DVR 0.383%/patient-year). Frequent as well as prolonged missing of prothrombin time tests was the main risk factor strongly associated with the thromboembolic complications (odds ratio 1.99). The proportion of INRs within target range of less than 60% in individual patient was the highly significant risk factor of both thromboembolic and overall embolic and bleeding complications (p<0.004 and p<0.002 respectively). CONCLUSION: In conclusion, the low-intensity therapeutic target range of INRs was adequate in patients with AVR and in sinus rhythm. However, the patients with replacement of the mitral valve were more likely to require higher target range of INRs, especially in the presence of atrial fibrillation, to achieve the practical levels of anticoagulation enough to prevent thromboembolic complications effectively. For the higher therapeutic target range of INRs between 2.0~3.0, further accumulation of clinical evidences are required. It is highly desirable to improve the patients' compliance under continuous instructions in visiting outpatient clinic and in taking daily Coumadin without omission and to keep INRs consistently within optimal range with tight control for minimization of chances and of periods of exposure to the risk of complications. And, particularly, patients with high risk of complications and with wide fluctuation of INRs should be better managed with frequent monitoring anticoagulation levels.
